275 related articles for article (PubMed ID: 9870249)
21. Why commonplace encounters turn to fatal attraction.
Sadelain M; Kieff E
Nat Genet; 1998 Oct; 20(2):103-4. PubMed ID: 9771693
[No Abstract] [Full Text] [Related]
22. Therapy for transplant-related lymphoproliferative diseases.
Benkerrou M; Durandy A; Fischer A
Hematol Oncol Clin North Am; 1993 Apr; 7(2):467-75. PubMed ID: 8385662
[TBL] [Abstract][Full Text] [Related]
23. [Post-transplantation lymphomas and Epstein-Barr virus].
Caillard S; Heibel F; Benaicha M; Moulin B
Nephrologie; 1998; 19(8):481-8. PubMed ID: 9894641
[TBL] [Abstract][Full Text] [Related]
24. Recurrent Epstein-Barr virus-associated lesions in organ transplant recipients.
Wu TT; Swerdlow SH; Locker J; Bahler D; Randhawa P; Yunis EJ; Dickman PS; Nalesnik MA
Hum Pathol; 1996 Feb; 27(2):157-64. PubMed ID: 8617457
[TBL] [Abstract][Full Text] [Related]
25. Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients.
Nalesnik MA; Rao AS; Furukawa H; Pham S; Zeevi A; Fung JJ; Klein G; Gritsch HA; Elder E; Whiteside TL; Starzl TE
Transplantation; 1997 May; 63(9):1200-5. PubMed ID: 9158009
[TBL] [Abstract][Full Text] [Related]
26. The expression of Epstein-Barr virus latent proteins is related to the pathological features of post-transplant lymphoproliferative disorders.
Delecluse HJ; Kremmer E; Rouault JP; Cour C; Bornkamm G; Berger F
Am J Pathol; 1995 May; 146(5):1113-20. PubMed ID: 7747805
[TBL] [Abstract][Full Text] [Related]
27. Reexamining post-transplant lymphoproliferative disorders: Newly recognized and enigmatic types.
Aguilera N; Gru AA
Semin Diagn Pathol; 2018 Jul; 35(4):236-246. PubMed ID: 29615296
[TBL] [Abstract][Full Text] [Related]
28. Role of donor versus recipient type Epstein-Barr virus in post-transplant lymphoproliferative disorders.
Haque T; Crawford DH
Springer Semin Immunopathol; 1998; 20(3-4):375-87. PubMed ID: 9870252
[No Abstract] [Full Text] [Related]
29. Analysis of the T-cell micro-environment in Epstein-Barr virus-related post-transplantation B lymphoproliferative disease.
Perera SM; Thomas JA; Burke M; Crawford DH
J Pathol; 1998 Feb; 184(2):177-84. PubMed ID: 9602709
[TBL] [Abstract][Full Text] [Related]
30. The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients.
Green M; Michaels MG; Webber SA; Rowe D; Reyes J
Pediatr Transplant; 1999 Nov; 3(4):271-81. PubMed ID: 10562971
[TBL] [Abstract][Full Text] [Related]
31. Epstein-Barr virus-related posttransplantation lymphoproliferative disorder involving pancreas allografts: histological differential diagnosis from acute allograft rejection.
Drachenberg CB; Abruzzo LV; Klassen DK; Bartlett ST; Johnson LB; Kuo PC; Kumar D; Papadimitriou JC
Hum Pathol; 1998 Jun; 29(6):569-77. PubMed ID: 9635676
[TBL] [Abstract][Full Text] [Related]
32. Transplantation-related lymphoproliferative disorder: a model for human immunodeficiency virus-related lymphomas.
Swinnen LJ
Semin Oncol; 2000 Aug; 27(4):402-8. PubMed ID: 10950366
[TBL] [Abstract][Full Text] [Related]
33. Identification of Epstein-Barr virus lytic activity in post-transplantation lymphoproliferative disease.
Montone KT; Hodinka RL; Salhany KE; Lavi E; Rostami A; Tomaszewski JE
Mod Pathol; 1996 Jun; 9(6):621-30. PubMed ID: 8782198
[TBL] [Abstract][Full Text] [Related]
34. Epstein-Barr virus gene expression in post-transplant lymphoproliferative disorders.
Rowe M; Niedobitek G; Young LS
Springer Semin Immunopathol; 1998; 20(3-4):389-403. PubMed ID: 9870253
[No Abstract] [Full Text] [Related]
35. The Immune Response to Epstein Barr Virus and Implications for Posttransplant Lymphoproliferative Disorder.
Martinez OM; Krams SM
Transplantation; 2017 Sep; 101(9):2009-2016. PubMed ID: 28376031
[TBL] [Abstract][Full Text] [Related]
36. Post-transplant lymphoproliferative disease in pediatric solid organ transplant recipients.
Wistinghausen B; Gross TG; Bollard C
Pediatr Hematol Oncol; 2013 Sep; 30(6):520-31. PubMed ID: 23802715
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-10 production by a B-cell line derived from human post-transplant lymphoproliferative disease.
Randhawa P; Nalesnik M; Demetris J; Zeevi A
Hematol Oncol; 1995; 13(1):13-8. PubMed ID: 7750924
[TBL] [Abstract][Full Text] [Related]
38. Central nervous system T-cell lymphoproliferative disorder in a patient with chronic active Epstein-Barr virus infection.
Ohga S; Takada H; Honda K; Inamura T; Gondo K; Ohshima K; Yamamoto M; Hara T
J Pediatr Hematol Oncol; 1999; 21(1):42-6. PubMed ID: 10029811
[TBL] [Abstract][Full Text] [Related]
39. T gamma/delta hepatosplenic lymphoma in a heart transplant patient after an Epstein-Barr virus positive lymphoproliferative disorder: a case report.
Kraus MD; Crawford DF; Kaleem Z; Shenoy S; MacArthur CA; Longtine JA
Cancer; 1998 Mar; 82(5):983-92. PubMed ID: 9486591
[TBL] [Abstract][Full Text] [Related]
40. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder.
Hart M; Thakral B; Yohe S; Balfour HH; Singh C; Spears M; McKenna RW
Am J Surg Pathol; 2014 Nov; 38(11):1522-9. PubMed ID: 25007145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
